FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Keyword: fertility
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Pausing hormone therapy to pursue pregnancy does not increase the short-term risk of early-stage cancer recurrence
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women with breast cancer who are considering pregnancy
Women who paused hormone therapy treatment of early-stage hormone receptor-positive (HR-positive) breast cancer to attempt to get pregnant had no increase in short-term recurrence. (Posted 11/3/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Progestin birth control may slightly increase breast cancer risk
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People who are using or have recently used birth control containing only the hormone progestin
Different types of birth control carry different cancer risks. Birth control using the hormone progestin slightly increases the risk of breast cancer during use and for a few years after use. (Posted 7/10/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium
Topic : Impact of new laws on cancer treatment during pregnancy
Relevance: Medium
Most relevant for: People who have cancer who are pregnant
The U.S. Supreme Court ruled in 2022 that abortion is no longer a protected right under the Constitution. This landmark decision leaves regulation of abortion to the states. Cancer treatment during pregnancy may now be impacted in states that have abortion bans or limitations. (Posted 5/31/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsStudy : Hormonal birth control may reduce ovarian cancer risk in people with BRCA mutations
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women with BRCA1 or BRCA2 mutations who are interested in reducing their ovarian cancer risk
Hormonal birth control pill is linked to reduced ovarian cancer among people with an inherited BRCA mutation. Longer-acting forms of birth control given by implant, injection or as an intrauterine device may be associated with lower ovarian cancer risk for people with an inherited BRCA mutation. (Posted 4/28/23)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Women can have safe pregnancies after breast cancer treatment
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women who have had breast cancer who are considering pregnancy.
In a large analysis of all published studies to date, most women who become pregnant after breast cancer treatment had safe pregnancies, with no increase in their cancer recurrence risk. Infants of mothers treated for breast cancer were more likely to have low birth weight, preterm birth and small size at birth but there was no increase in birth defects. Breast cancer survivors who became pregnant had a similar risk of recurrence and survival as survivors who did not become pregnant. (posted 6/24/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Birth control pills may offer long-term protection against endometrial and ovarian cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People concerned about endometrial, ovarian or breast cancer risk
A large study showed that birth control pills may protect against endometrial and ovarian cancers, even years after use was discontinued. (posted 6/1/21)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women considering breastfeeding who have inherited BRCA mutations.
Data from a large-scale study suggests that breastfeeding may protect against ovarian cancer in women with inherited mutations in BRCA1 or BRCA2. (1/28/21)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Women support delayed removal of ovaries
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women at high risk of ovarian cancer who are considering undergoing risk-reducing surgery.
Risk-reducing early removal of fallopian tubes followed by removal of ovaries at a later date was acceptable to women at high risk of ovarian cancer due to an inherited mutation in a recent study. This was especially true for women worried about sexual dysfunction associated with surgical menopause. (12/24/20)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation
The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Is it safe for BRCA mutation carriers to become pregnant following breast cancer?
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women with a BRCA mutation who are considering pregnancy after breast cancer
New research shows that pregnancy after breast cancer is safe for women with BRCA mutations and their babies. (9/4/19)
Read More